Nothing Special   »   [go: up one dir, main page]

WO2000070099A3 - Differential gene expression in specific regions of the brain in neurodegenerative diseases - Google Patents

Differential gene expression in specific regions of the brain in neurodegenerative diseases Download PDF

Info

Publication number
WO2000070099A3
WO2000070099A3 PCT/US2000/013951 US0013951W WO0070099A3 WO 2000070099 A3 WO2000070099 A3 WO 2000070099A3 US 0013951 W US0013951 W US 0013951W WO 0070099 A3 WO0070099 A3 WO 0070099A3
Authority
WO
WIPO (PCT)
Prior art keywords
contactin
present
neurodegenerative disease
compounds
compositions
Prior art date
Application number
PCT/US2000/013951
Other languages
French (fr)
Other versions
WO2000070099A2 (en
Inventor
Jung-Joo Hwang
K David Becker
Robert E Davis
Original Assignee
Mitokor
Hwang Jung Joo
K David Becker
Robert E Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor, Hwang Jung Joo, K David Becker, Robert E Davis filed Critical Mitokor
Priority to EP00936142A priority Critical patent/EP1208228A2/en
Priority to JP2000618504A priority patent/JP2003504007A/en
Priority to CA002371212A priority patent/CA2371212A1/en
Priority to AU51503/00A priority patent/AU5150300A/en
Publication of WO2000070099A2 publication Critical patent/WO2000070099A2/en
Publication of WO2000070099A3 publication Critical patent/WO2000070099A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides nucleic acid molecules that can function as PCR primers for the detection of contactin mRNA in a sample. Such nucleic acid molecules can be labeled and can be provided in a kit. The present invention also includes a method of detecting the presence of a neurodegenerative disease such as multiple sclerosis, including providing a sample from a patient and measuring the amount of contactin protein or contactin mRNA expressed in the sample. The present invention further provides a method for identifying which patents having a neurodegenerative disease are likely to respond to a treatment for a neurodegenerative disease. The present invention further includes compositions of matter that include an isolated cell or a cell in culture that expresses an increased or decreased amount of contactin as compared to a control cell. The present invention also includes a method for screening compounds for the activity of reducing or enhancing the expression of contactin and compositions or compounds, including pharmaceutical compositions, identified by this method. Also included are methods of treating a neurodegenerative disease using such compositions or compounds. The present invention also includes methods of identifying pharmaceutical targets for compounds that modulate contactin expression or activity and targets identified by such methods.
PCT/US2000/013951 1999-05-19 2000-05-19 Differential gene expression in specific regions of the brain in neurodegenerative diseases WO2000070099A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00936142A EP1208228A2 (en) 1999-05-19 2000-05-19 Differential gene expression in specific regions of the brain in neurodegenerative diseases
JP2000618504A JP2003504007A (en) 1999-05-19 2000-05-19 Different gene expression in specific regions of the brain in neurodegenerative diseases
CA002371212A CA2371212A1 (en) 1999-05-19 2000-05-19 Differential gene expression in specific regions of the brain in neurodegenerative diseases
AU51503/00A AU5150300A (en) 1999-05-19 2000-05-19 Differential gene expression in specific regions of the brain in neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13479099P 1999-05-19 1999-05-19
US60/134,790 1999-05-19
US57461300A 2000-05-18 2000-05-18
US09/574,613 2000-05-18

Publications (2)

Publication Number Publication Date
WO2000070099A2 WO2000070099A2 (en) 2000-11-23
WO2000070099A3 true WO2000070099A3 (en) 2002-04-04

Family

ID=26832668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013951 WO2000070099A2 (en) 1999-05-19 2000-05-19 Differential gene expression in specific regions of the brain in neurodegenerative diseases

Country Status (5)

Country Link
EP (1) EP1208228A2 (en)
JP (1) JP2003504007A (en)
AU (1) AU5150300A (en)
CA (1) CA2371212A1 (en)
WO (1) WO2000070099A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001240820A1 (en) * 2000-03-15 2001-09-24 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular dementia
WO2002040996A2 (en) * 2000-11-08 2002-05-23 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
DE08002964T1 (en) 2001-02-27 2009-09-03 Blanchette Rockefeller Neurosciences Institute Alzheimer's diagnosis based on mitogen-activated protein kinase phosphorylation
EP1427858A2 (en) * 2001-09-12 2004-06-16 F. Hoffmann-La Roche Ag Specific markers for multiple sclerosis
EP1497661B1 (en) * 2002-04-24 2009-11-25 EVOTEC Neurosciences GmbH Diagnostic use of ensadin-0477 gene and protein for neurodegenerative diseases
US20080187911A1 (en) * 2003-01-30 2008-08-07 Research Development Foundation Methods and compositions for analysis of mitochondrial-related gene expression
CA2582270A1 (en) * 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
WO2009020058A1 (en) * 2007-08-03 2009-02-12 Keio University Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion
CA2941035A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
WO2010014588A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
JP6058395B2 (en) 2009-10-02 2017-01-11 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Fibroblast growth patterns for the diagnosis of Alzheimer's disease
JP6563193B2 (en) 2011-11-13 2019-08-21 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Esters of DCPLA and methods of treatment using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035373A2 (en) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Nucleic acid molecules encoding human contactin
WO1997015690A1 (en) * 1995-10-24 1997-05-01 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying dna sequences in a sample without sequencing
US5739289A (en) * 1993-03-26 1998-04-14 Becton, Dickinson And Company Monoclonal antibody to human cell adhesion molecule
WO1998049342A1 (en) * 1997-04-30 1998-11-05 Forskningsparken I Ås As Method of preparing a standard diagnostic gene transcript pattern
US5888498A (en) * 1995-03-03 1999-03-30 Mitokor Cellular and animal models for diseases associated with mitochondrial defects

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739289A (en) * 1993-03-26 1998-04-14 Becton, Dickinson And Company Monoclonal antibody to human cell adhesion molecule
WO1995035373A2 (en) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Nucleic acid molecules encoding human contactin
US5888498A (en) * 1995-03-03 1999-03-30 Mitokor Cellular and animal models for diseases associated with mitochondrial defects
WO1997015690A1 (en) * 1995-10-24 1997-05-01 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying dna sequences in a sample without sequencing
WO1998049342A1 (en) * 1997-04-30 1998-11-05 Forskningsparken I Ås As Method of preparing a standard diagnostic gene transcript pattern

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLAGGE A ET AL: "The gene of the neural cell recognition molecule F11: conserved exon-intron arrangement in genes of neural members of the immunoglobulin superfamily", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 192, no. 2, 1997, pages 215 - 225, XP004081714, ISSN: 0378-1119 *
SHIMAZAKI K ET AL: "Age-related decline of f3/contactin in rat hippocampus", NEUROSCIENCE LETTERS, vol. 245, no. 2, 1998, pages 117 - 20, XP001024403 *

Also Published As

Publication number Publication date
AU5150300A (en) 2000-12-05
JP2003504007A (en) 2003-02-04
EP1208228A2 (en) 2002-05-29
WO2000070099A2 (en) 2000-11-23
CA2371212A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
Condliffe et al. Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain
Kato et al. Comprehensive DNA methylation and hydroxymethylation analysis in the human brain and its implication in mental disorders
Nieminuszczy et al. The DNA fibre technique–tracking helicases at work
Zhu et al. MicroRNA-494 improves functional recovery and inhibits apoptosis by modulating PTEN/AKT/mTOR pathway in rats after spinal cord injury
Vannini et al. Effects of a complex mixture of therapeutic drugs on unicellular algae Pseudokirchneriella subcapitata
Kumar et al. Tet1 oxidase regulates neuronal gene transcription, active DNA hydroxymethylation, object location memory, and threat recognition memory
Lu et al. DNA methylation, a hand behind neurodegenerative diseases
CN110791560B (en) miRNA marker for diagnosing and/or treating Alzheimer disease
WO2000070099A3 (en) Differential gene expression in specific regions of the brain in neurodegenerative diseases
Liu et al. PARP-1 enhances the mismatch-dependence of 5′-directed excision in human mismatch repair in vitro
WO2006096737A3 (en) Diagnostic and therapeutic target for macular degeneration
Sarasin et al. New insights for understanding the transcription-coupled repair pathway
Rezende et al. Knock out of the NADPH oxidase Nox4 has no impact on life span in mice
Guo et al. Genome-wide antagonism between 5-hydroxymethylcytosine and DNA methylation in the adult mouse brain
Phillips et al. The Drosophila black enigma: the molecular and behavioural characterization of the black1 mutant allele
WO2010011283A3 (en) Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases
Tan et al. Small Maf functions in the maintenance of germline stem cells in the Drosophila testis
Ali et al. RNA extraction from human articular cartilage by chondrocyte isolation
US11359245B2 (en) Method for determining decrease in functions of hippocampus by using correlation between micro RNA and NMDA receptor, method for inhibiting decrease in functions, and method for screening for inhibitors of decrease in functions
AU2016282350A1 (en) Targeted enrichment of long nucleotide sequences using microfluidic partitioning
de Melo et al. XPC deficiency is related to APE1 and OGG1 expression and function
CN103374575B (en) CYP4V2 gene mutant and application thereof
JP2010535501A (en) Methods to identify individuals at risk of thiopurine drug resistance and thiopurine drug intolerance
Rybin et al. Emerging technologies for genome-wide profiling of DNA breakage
Rodriguez-Corona et al. Novel ribonuclease activity differs between fibrillarins from Arabidopsis thaliana

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371212

Country of ref document: CA

Ref country code: CA

Ref document number: 2371212

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 51503/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618504

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000936142

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000936142

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000936142

Country of ref document: EP